title: Dexmedetomidine protects against ischemia/reperfusion injury in rat kidney.
abstract: OBJECTIVE
  Ischemia/reperfusion (I/R) injury in the kidney during perioperative period remains the leading cause of acute renal failure. The purpose of this experimental study was to determine the role of dexmedetomidine (Dex) on renal I/R injury in rats.
  
  
  METHODS
  Male Wistar rats, subjected to renal ischemia for 45 min, were either untreated or treated with dexmedetomidine 30 min prior to renal ischemia. A sham-operated group served as the control. Renal function [serum creatinine, blood urea nitrogen, serum Cystatin C and neutrophil gelatinase-associated lipocalin (NGAL)], histology, apoptosis and expression of the phosphorylations of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) were assessed.
  
  
  RESULTS
  The animals treated with dexmedetomidine improved renal functional recovery, especially reducing the level of serum Cystatin C and NGAL at early time after ischemia, attenuated histological lesions, reduced tubular epithelial apoptosis and inhibited the phosphorylation of JAK2 and its downstream molecule STAT3, contributing to ameliorating renal I/R injury.
  
  
  CONCLUSIONS
  Our data suggest that anti-apoptosis effect contributes to the renoprotection of dexmedetomidine, via inhibiting JAK2/STAT3 signaling pathway partially.
authors.affiliation: Department of Anesthesiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. hongguangbaocn@126.com.
authors.forename: Y-N
authors.initials: YN
authors.lastname: Si
authors.forename: H-G
authors.initials: HG
authors.lastname: Bao
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: X-L
authors.initials: XL
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Shen
authors.forename: J-S
authors.initials: JS
authors.lastname: Wang
authors.forename: X-B
authors.initials: XB
authors.lastname: Yang
mesh_terms: D000209:Acute-Phase Proteins; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism; D001806:Blood Urea Nitrogen; D003401:Creatine / Q000097:blood; D055316:Cystatin C / Q000097:blood; D020927:Dexmedetomidine / Q000494:pharmacology / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007684:Kidney Tubules / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood; D008297:Male; D009336:Necrosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000097:blood; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D050796:STAT3 Transcription Factor / Q000378:metabolism
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; C525032:Cst3 protein, rat; D055316:Cystatin C; C097278:Lcn2 protein, rat; D000071068:Lipocalin-2; D054834:Lipocalins; D020011:Protective Agents; D011518:Proto-Oncogene Proteins; D050796:STAT3 Transcription Factor; C494088:Stat3 protein, rat; D020927:Dexmedetomidine; C507927:Jak2 protein, rat; D053614:Janus Kinase 2; D003401:Creatine